secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aspire Biopharma Holdings, Inc. (ASBP)
CIK:        0001847345
Form:       8-K
Filed at:   2025-02-10T23:59:59+00:00
Accession:  0001493152-25-005641
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PowerUp shareholders approve merger with Aspire Biopharma; redemptions of ~$5.8M
--------------------------------------------------------------------------------

- All proposals approved at Feb 4 meeting, including business combination, domestication, and charter changes.
- 507,631 shares redeemed for $5.8M ($11.43/share), leaving ~$5.8M removed from trust.
- Closing expected before Feb 17, 2025; combined company to trade as ASBP (common) and ASBPW (warrants) on Nasdaq.
- Seven directors elected to staggered board, including Kraig Higginson, Michael Howe, Gary Stein, others.
- Adjournment proposal not needed due to sufficient votes for all proposals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225005641/0001493152-25-005641-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1847345/000149315225005641/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-005641

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer